Erratum to: Strong predictive value of mannose-binding lectin levels for cardiovascular risk of hemodialysis patients

Erratum to: J Transl Med (2016) 14:236
DOI:10.1186/s12967-016-0995-5

Unfortunately, the original version of this article [1] contained errors in the main text and in Tables 2 and 3. Tables 2 and 3 were included incorrectly. The correct Tables 2 and 3 have been updated in the original article and are also included correctly in this erratum.

Additionally, the following section has been corrected:

However, after adjustment MBL for these confounders levels remained associated with cardiovascular events, indicating a direct and independent effect of MBL on cardiovascular risk.

Should read:

However, after adjustment for these confounders, MBL levels remained associated with cardiovascular events, indicating a direct and independent effect of MBL on cardiovascular risk.
| MBL range (ng/mL) | All (n = 107) | MBL low 319 < ng/mL (n = 26) | MBL high 319 ≥ ng/mL (n = 81) | P** < 0.001 | R | P# |
|------------------|----------------|-----------------------------|-----------------------------|-------------|---|----|
| **Demographics** |                |                             |                             |             |   |     |
| Age, years       | 62.5 ± 15.6    | 65.3 ± 12.1                 | 61.56 ± 16.6                | 0.3         | −0.26 | 0.007 |
| Male gender, n (%) | 71 (66)       | 17 (65)                     | 54 (67)                     | 1.0         |       |     |
| Current diabetes, n (%) | 25 (24)     | 9 (35)                      | 16 (20)                     | 0.2         |       |     |
| Hypertension, n (%) | 85 (84)       | 22 (88)                     | 63 (83)                     | 0.8         |       |     |
| Cardiovascular history, n (%) | 26 (25)     | 9 (35)                      | 15 (19)                     | 0.1         |       |     |
| BMI, kg/m²       | 25.8 ± 4.4     | 27.0 ± 4.5                  | 25.4 ± 4.4                  | 0.1         | −0.03 | 0.8  |
| **Hemodialysis** |                |                             |                             |             |   |     |
| Dialysis vintage, months | 25.5 [8.5–52.3] | 18.2 [7.0–47.7] | 32.8 [9.1–53.3] | 0.2 | −0.01 | 0.9 |
| Primary renal disease, n (%) | 18 (17)       | 4 (15)                      | 14 (17)                     | 1.0         |       |     |
| Hypertension      | 14 (13)        | 5 (19)                      | 9 (11)                      | 0.3         |       |     |
| Diabetest        | 13 (12)        | 3 (12)                      | 10 (12)                     | 1.0         |       |     |
| FSGS             | 9 (8)          | 4 (15)                      | 5 (6)                       | 0.2         |       |     |
| IgA nephropathy   | 4 (4)          | 0 (0)                       | 4 (5)                       | 0.6         |       |     |
| Chronic pyelonephritis | 3 (3)        | 0 (0)                       | 3 (4)                       | 1.0         |       |     |
| Glomerulonephritis | 13 (12)        | 2 (8)                       | 11 (14)                     | 0.7         |       |     |
| Other diagnoses   | 16 (16)        | 6 (23)                      | 10 (12)                     | 0.2         |       |     |
| Unknown           | 17 (16)        | 2 (8)                       | 15 (19)                     | 0.2         |       |     |
| Ultrafiltration volume, L | 2.55 ± 0.78  | 2.54 ± 0.82                 | 2.56 ± 0.78                 | 0.9         | −0.01 | 0.9 |
| Ultrafiltration rate, mL/kg/h | 8.56 ± 2.63 | 7.81 ± 2.39                 | 8.80 ± 2.67                 | 0.1         | 0.04  | 0.7  |
| **Systolic blood pressure** |                |                             |                             |             |   |     |
| Predialysis, mmHg | 140.4 ± 25.1  | 144.7 ± 26.4                | 139.1 ± 24.7                | 0.3         | −0.17 | 0.08 |
| Postdialysis, mmHg | 131.8 ± 25.6 | 136 ± 24.3                  | 130.4 ± 26.0                | 0.4         | −0.24 | 0.02 |
| **Heart rate**    |                |                             |                             |             |   |     |
| Predialysis, bpm | 73 [63–82]    | 71 [62–82]                  | 74 [64–82]                  | 0.3         | 0.11  | 0.3  |
| Postdialysis, bpm | 79 [69–87]   | 75 [65–86]                  | 79 [69–88]                  | 0.4         | 0.13  | 0.2  |
| Kidney transplant, n (%) | 21 (20)       | 4 (15)                      | 17 (21)                     | 0.8         |       |     |
| **Laboratory measurements** |                |                             |                             |             |   |     |
| Hematocrit, %     | 34.9 ± 3.8    | 34.5 ± 4.1                  | 35.0 ± 3.7                  | 0.6         | 0.04  | 0.7  |
| HbA1c, mmol/mol   | 5.68 ± 0.98   | 5.80 ± 0.97                 | 5.63 ± 0.98                 | 0.5         | −0.15 | 0.2  |
| Albumin, g/L      | 39 [37–42]    | 39 [37–42]                  | 39 [37–42]                  | 0.9         | 0.01  | 0.9  |
| pH                | 7.37 [7.34–7.39] | 7.37 [7.32–7.39] | 7.37 [7.34–7.39] | 0.7         | 0.05  | 0.6  |
| Calcium, mmol/L   | 2.31 ± 0.16   | 2.31 ± 0.15                 | 2.32 ± 0.16                 | 0.9         | 0.03  | 0.7  |
| Phosphate, mmol/L | 1.67 ± 0.53   | 1.82 ± 0.47                 | 1.65 ± 0.54                 | 0.2         | −0.00 | 0.9  |
| hsCRP, mg/L       | 6.7 [2.8–10.9]| 6.1 [1.4–12.0]              | 6.7 [3.0–10.9]              | 0.7         | 0.10  | 0.3  |
| **Medication**    |                |                             |                             |             |   |     |
| Aspirin, n (%)    | 57 (54)       | 11 (42)                     | 46 (64)                     | 0.3         |       |     |
| Calcium channel blockers, n (%) | 14 (13)       | 3 (12)                      | 11 (14)                     | 1.0         |       |     |
| β-Blocker, n (%)  | 61 (57)       | 18 (69)                     | 43 (53)                     | 0.2         |       |     |
| ACE inhibitor, n (%) | 10 (10)    | 3 (12)                      | 7 (9)                       | 0.7         |       |     |
| AT2-receptor antagonists, n (%) | 14 (13)       | 2 (8)                       | 12 (15)                     | 0.5         |       |     |
| Statin, n (%)     | 20 (19)       | 5 (19)                      | 15 (19)                     | 1.0         |       |     |
| Diuretics, n (%)  | 8 (8)         | 3 (12)                      | 5 (6)                       | 0.4         |       |     |

Italic values used to show which statistical testing was significant (below 0.05)

Data are presented as mean ± SD or median [IQR]

BMI body mass index, ADPKD autosomal dominant polycystic kidney disease, FSGS focal segmental glomerulosclerosis, HbA1c hemoglobin A1c, pH potential hydrogen, hsCRP high sensitive C-relative protein, ACE inhibitor angiotensin-converting-enzyme inhibitor, AT2 receptor antagonists Angiotensin II receptor antagonists

P* indicates P value for the difference in baseline characteristics between the MBL groups, tested by Student’s t test or Mann–Whitney U test for continuous variables and with χ² test for categorical variables; R indicates Spearman correlation coefficient between MBL levels and the baseline characteristic; P# indicates the corresponding P value.
## Table 3  
Associations of MBL levels with cardiovascular events and cardiac events in 107 chronic hemodialysis patients

| Low MBL |
|---------|
| HR | 95 % CI | P |
|------|---------|---|
| Cardiovascular events |
| Model 1 | 2.64 | 1.36–5.13 | 0.004 |
| Model 2 | 2.75 | 1.39–5.44 | 0.004 |
| Model 3 | 2.94 | 1.45–5.94 | 0.003 |
| Model 4 | 3.55 | 1.70–7.40 | 0.001 |
| Model 5 | 3.98 | 1.88–8.42 | <0.001 |
| Log MBL continuous |
| HR (per SD) | 95 % CI | P |
|------|---------|---|
| Cardiovascular events |
| Model 1 | 0.64 | 0.46–0.90 | 0.01 |
| Model 2 | 0.61 | 0.43–0.88 | 0.008 |
| Model 3 | 0.61 | 0.42–0.89 | 0.01 |
| Model 4 | 0.58 | 0.40–0.84 | 0.004 |
| Model 5 | 0.56 | 0.38–0.81 | 0.002 |
| Cardiac events |
| Model 1 | 2.60 | 1.10–6.18 | 0.03 |
| Model 2 | 2.49 | 1.04–5.96 | 0.04 |
| Model 3 | 2.65 | 1.08–6.55 | 0.03 |
| Model 4 | 3.82 | 1.48–9.87 | 0.006 |
| Model 5 | 3.96 | 1.49–10.54 | 0.006 |

Model 1: crude  
Model 2: adjusted for age and gender  
Model 3: adjusted for model 2 plus ultrafiltration volume and dialysis vintage  
Model 4: adjusted for model 3 plus cardiovascular history, diabetes and post-HD systolic blood pressure  
Model 5: adjusted for model 4 plus hsCRP

Data are presented as hazard ratio (HR) plus 95 % confidence interval (CI) according to the cut-off of MBL and per standard deviation (SD) MBL increase  
Italic values used to show which statistical testing was significant (below 0.05)

**MBL** mannose-binding lectin, **HD** hemodialysis, **hsCRP** high sensitive C-reactive protein

### Author details

1. Division of Nephrology, Department of Internal Medicine, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands  
2. Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands  
3. Department of Nephrology, Leiden University Medical Center, University of Leiden, Leiden, The Netherlands

### Reference

1. Poppelaars F, Gaya da Costa M, Berger SP, Assa S, Meter-Arkema AH, Daha MR, van Son WJ, Franssen CFM, Seelen MAJ. Strong predictive value of mannose-binding lectin levels for cardiovascular risk of hemodialysis patients. J Transl Med. 2016;14:236. doi:10.1186/s12967-016-0995-5.

The online version of the original article can be found under doi:10.1186/s12967-016-0995-5

Published online: 24 August 2016

---

Submit your next manuscript to BioMed Central and we will help you at every step:  
- We accept pre-submission inquiries  
- Our selector tool helps you to find the most relevant journal  
- We provide round the clock customer support  
- Convenient online submission  
- Thorough peer review  
- Inclusion in PubMed and all major indexing services  
- Maximum visibility for your research

Submit your manuscript at www.biomedcentral.com/submit